Healthy, HIV-negative subjects are being recruited for investigational studies of vaccines to prevent infectious diseases (other than HIV) through protocol VRC-300 (NIH 03-I-0285). In FY 04 the VRC completed recruitment of 27 subjects for a clinical trial of an investigational Ebola vaccine trial. The screening study was used to determine if the subject met eligibility requirements for participation in Phase I trials of preventative vaccines. Educational materials on vaccines were reviewed with and provided to subjects before enrollment into the vaccine study. The Ebola vaccine study is included in the VRC Biodefense mission.
| Sullivan, Nancy J; Martin, Julie E; Graham, Barney S et al. (2009) Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol 7:393-400 |
| Martin, Julie E; Pierson, Theodore C; Hubka, Sarah et al. (2007) A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis 196:1732-40 |
| Martin, Julie E; Sullivan, Nancy J; Enama, Mary E et al. (2006) A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol 13:1267-77 |
